Related Experiment Videos
Biomarkers and diagnostics in heart failure.
Hanna K Gaggin1, James L Januzzi
1Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, Yawkey 5700, Boston, MA, USA.
Biochimica Et Biophysica Acta
|January 15, 2013
Summary
Biomarkers like B-type natriuretic peptide are crucial for heart failure (HF) management. Novel biomarkers show promise for prognosis but require further clinical validation.
Area of Science:
- Cardiology
- Biomarker Discovery
Background:
- Heart failure (HF) management relies heavily on biomarkers.
- B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are established gold standards for HF diagnosis and prognosis.
- Natriuretic peptide-guided HF management strategies show promise.
Purpose of the Study:
- To review the impact of established and emerging biomarkers in heart failure.
- To discuss the potential of novel biomarkers in predicting HF prognosis.
- To highlight the need for further clinical validation of new biomarkers.
Main Methods:
- Review of current literature on HF biomarkers.
- Analysis of pathophysiological processes reflected by different biomarkers.
- Evaluation of the clinical utility of novel biomarkers.
Main Results:
- BNP and NT-proBNP are essential for HF evaluation and management.
- Emerging biomarkers (MR-proANP, MR-proADM, troponins, sST2, GDF-15, Galectin-3) reflect diverse HF pathologies.
- These novel biomarkers demonstrate potential for prognostic assessment beyond natriuretic peptides.
Conclusions:
- Established biomarkers significantly influence HF patient care.
- Novel biomarkers offer complementary prognostic information but require further clinical definition.
- Continued research is essential to integrate new biomarkers into routine HF management.
Keywords:
ADHEREADMANPAUCAcute Decompensated Heart Failure National RegistryAdrenomedullinArea under the curveAtrial natriuretic peptideB-type natriuretic peptideBACHBNPBiomarkerBiomarkers in Acute Heart FailureCICORONAConfidence intervalControlled Rosuvastatin Multinational Trial in Heart FailureDiagnosisGDF-15GISSI-HFGrowth differentiation factor-15Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca–Heart FailureHFHF with preserved left ventricular ejection fractionHFpEFHRHazard ratioHeart failureHighly sensitive troponinHighly sensitive troponin IHighly sensitive troponin TICONInternational Collaborative of NT-proBNPLVSDLeft ventricular systolic dysfunctionMIMR-proADMMR-proANPManagementMid-regional pro adrenomedullinMid-regional pro atrial natriuretic peptideMyocardial infarctionN-terminal pro B-type natriuretic peptideNHANESNT-proBNPNYHANational Health and Nutrition Examination SurveyNew York Heart AssociationPRIDEProBNP Investigation of Dyspnea in the Emergency DepartmentPrognosisST2 ligandST2LSoluble ST2Val-HeFTValsartan Heart Failure TrialhsTnhsTnIhsTnTsST2Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...